Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
19.83
+0.03 (0.15%)
At close: Nov 13, 2026, 4:00 PM EST
19.83
0.00 (0.01%)
After-hours: Nov 13, 2026, 7:30 PM EST
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $465.83K in the twelve months ending September 30, 2026, down -98.14% year-over-year. In the year 2025, Silence Therapeutics had annual revenue of $568.83K, down -98.66%.
Revenue (ttm)
$465.83K
Revenue Growth
-98.14%
P/S Ratio
2,705.01
Revenue / Employee
$5,182
Employees
88
Market Cap
1.23B
Revenue by Geography
- UK 43.11M 99.7%
- Germany 144.00K 0.3%
Fiscal year ended Dec 31, 2024 See the full Silence Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 568.83K | -41.89M | -98.66% |
| Dec 31, 2024 | 42.45M | 10.81M | 34.17% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.78M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | -70.63K | -26.71% |
| Dec 31, 2012 | 264.40K | -812.57K | -75.45% |
| Dec 31, 2011 | 1.08M | -2.61M | -70.75% |
| Dec 31, 2010 | 3.68M | 893.28K | 32.03% |
| Dec 31, 2009 | 2.79M | -435.52K | -13.51% |
| Dec 31, 2008 | 3.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UroGen Pharma | 250.25M |
| Ascentage Pharma Group International | 94.61M |
| Nektar Therapeutics | 52.19M |
| Omeros | 38.42M |
| Inhibrx Biosciences | 2.00M |
SLN News
- 3 days ago - Silence Therapeutics reports Q3 EPS (8c), consensus (13c) - TheFly
- 3 days ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results - Business Wire
- 3 days ago - Silence Therapeutics Proxy statement: Proxy filing - Filings
- 3 days ago - Silence Therapeutics Earnings release: Q3 2026 - Filings
- 3 days ago - Silence Therapeutics Quarterly report: Q3 2026 - Filings
- 11 days ago - Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026 - Business Wire
- 25 days ago - Silence Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 26 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG) - GlobeNewsWire